Unknown PHASE2 INTERVENTIONAL 1-arm NCT06192784

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

A Phase 2, Open-label, Single Arm Study of Combined Drug-eluting Beads-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Sponsor: Chinese Cooperative Group of Liver Cancer

Conditions Cholangiocarcinoma Non-resectable

Interventions DEB-TACE Lenvatinib plus pucotenlimab

Updated 5 times since 2024 Last updated: Jan 5, 2024 Started: Dec 9, 2023 Primary completion: Jan 31, 2025 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cholangiocarcinoma Non-resectable, this trial is ongoing. The trial is conducted by Chinese Cooperative Group of Liver Cancer and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE2

First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Cooperative Group of Liver Cancer
Geneplus-Beijing Co. Ltd.
Tongji Hospital

Data source: Tongji Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China